Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors.
Fiche publication
Date publication
janvier 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CRIBIER Bernard
Tous les auteurs :
Macagno N, Sohier P, Kervarrec T, Pissaloux D, Jullie ML, Cribier B, Battistella M
Lien Pubmed
Résumé
Cutaneous sweat gland tumors are a subset of adnexal neoplasms that derive or differentiate into the sweat apparatus. Their great diversity, rarity, and complex terminology make their pathological diagnosis challenging. Recent findings have revealed a wide spectrum of oncogenic drivers, several of which are of diagnostic interest for pathologists. Most of these molecular alterations are represented by gene fusions, which are shared with other homologous neoplasms occurring in organs containing exocrine glands, such as salivary and breast glands, which show similarities to the sweat apparatus. This review aims to provide a synthesis of the most recent immunohistochemical and molecular markers used for the diagnosis of sweat gland tumors and to highlight their relationship with similar tumors in other organs. It will cover adenoid cystic carcinoma (, and fusion), cutaneous mixed tumor ( fusion), cylindroma and spiradenoma and their carcinomas thereof (NF-κB activation through inactivation or hotspot mutation), hidradenoma and hidradenocarcinoma ( fusion), myoepithelioma ( and fusion), poroma and porocarcinoma (, and fusion), secretory carcinoma (, fusion), tubular adenoma and syringo-cystadenoma papilliferum ( and activating mutations). Sweat gland tumors for which there are no known molecular abnormalities will also be briefly discussed, as well as potential future developments.
Mots clés
ALKP1, BRAF, CYLD, ETV6, EWSR1, FUS, HRAS, MAML2, MYB, MYBL1, NFIB, NTRK3, NUTM1, PLAG1, YAP1, adenoid cystic carcinoma, chondroid syringoma, cylindroma, hidradenoma, mixed tumor, myoepithelioma, porocarcinoma, poroid hidradenoma, poroma, secretory carcinoma, spiradenoma, syringocystadenoma papilliferum, tubular adenoma
Référence
Cancers (Basel). 2022 Jan 18;14(3):